Abstract
Diffuse large B-cell lymphoma (DLBCL), being the most common lymphoma entity, accounting for 30 % - 40 % of newly diagnosed non-Hodgkin lymphomas, is a kind of highly heterogeneous lymphoma with different pathogenesis, clinical manifestations, morphological characteristics, the immune phenotype, molecular subgroup and clinical outcomes. Gene sequencing of DLBCL has redefined the genetic landscape of the disease by identifying recurrent single nucleotide variants, which provides more powerful evidence to support accurate diagnosis and targeted treatment in DLBCL molecular subtypes. Key words: Lymphoma, large B-cell, diffuse; Genes; Molecular targeted therapy
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
